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T reg cells are important for the control of auto-
immune diseases and for limiting immune re-
sponses (1). “Natural” T reg cells can be identified 
by CD25 surface expression in both mice and 
humans, and express high levels of CTLA-4 (2). 
They mature in the thymus (1) or in the pe-
riphery after tolerogenic priming (3), and are 
anergic in vitro because they lack an IL-2– 
producing capacity. Nevertheless, T reg cells 
proliferate in vivo (4, 5) and are highly suscep-
tible to apoptosis (6). They inhibit T cell prim-
ing in vitro by a not fully understood cell 
contact–dependent mechanism (2). It is believed 
that these cells represent an independent T cell 
lineage that is determined by the transcription 
factor Foxp3 (1). The TCR repertoire of nat-
ural T reg cells is biased toward autoreactivity 
(7), and they have been shown to prevent auto-
immune diseases in several different models (1). 
On the other hand, “adaptive” type 1 regula-
tory (Tr1) cells have also been shown to be 
important for control of autoimmune diseases (8). 
These  cells  do  not  belong  to  the  natural   
T reg cell lineage (9, 10) and are characterized 
by their capacity to produce IL-10 and to in-
hibit immune responses in an IL-10–depen-
dent manner (8, 10, 11). Tr1-like populations 
can be generated in vitro in various ways, in-
cluding  repetitive  priming  with  immature 
DCs, IL-10 plus IFN-, or immune-suppres-
sive  drugs  (8,  12–14).  Interestingly,  IL-10–
producing Th1 cells have been recently shown 
to prevent immunopathology in chronic para-
site infections in vivo (15, 16), but their rela-
tionship to Tr1 cells is currently unclear because 
not all described Tr1 populations also pro-
duce IFN-.
Although various Tr1-like populations can 
be generated, their identity and phenotype in 
human blood is currently unknown. Recently, 
it was shown that human CD25+ T reg cells 
express low levels of CD127 (17, 18), the 
IL-7R chain that is important for survival and 
homeostatic maintenance of CD4+ memory 
T cells (19). Based on this observation, it was 
speculated that adaptive T reg cells might be 
present among CD25IL-7Rlo cells (20). Con-
sistently, adaptive mouse T reg cells that down-
regulate  inflammatory  responses  to  malaria 
parasites had a CD127CD25 phenotype (21). 
In this report, we show that human blood 
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in the mouse (22). In conclusion, the cytokine profile of 
circulating IL-7R cells (i.e., cosecretion of IFN- and IL-10 
combined with low IL-2 production) is consistent with that 
reported originally for adaptive regulatory Tr1 cells gener-
ated in vitro (8, 14). Coproduction of IFN- and IL-10 is 
also characteristic for Th1 cells that prevent immunopathol-
ogy upon chronic mouse Toxoplasma or Leishmania infections 
(15, 16). The production of IFN- distinguishes human 
IL-7R cells, however, from Tr1-like cells generated upon 
mouse malaria infection (21) and from some Tr1-like pop-
ulations generated in vitro (12, 13).
CD4+IL-7R T cells have a low expansion potential
IL-7R expression is characteristic for mouse CD4+ memory 
T cells because they require IL-7 for their antigen-indepen-
dent maintenance (19). Memory T cells are characterized by 
a high secondary expansion potential, whereas effector cells 
die upon restimulation and T reg cells are anergic in vitro. 
To analyze the secondary expansion potentials of the purified 
CD4+ T cell subsets, cells were labeled with CFSE and stim-
ulated with immobilized anti-CD3 antibodies in the absence 
or presence of anti-CD28 antibodies or exogenous IL-2 
(Fig. 2 A). IL-7R+ memory phenotype cells proliferated effi-
ciently upon stimulation with anti-CD3, and expansion was 
further enhanced by the addition of IL-2 or anti-CD28 anti-
bodies. Conversely, CD25+ T reg cells and IL-7R cells failed 
to proliferate upon anti-CD3 stimulation alone, but IL-7R 
cells proliferated when exogenous IL-2 was added. Both sub-
sets proliferated upon addition of anti-CD28, but low num-
bers of IL-7R cells were recovered after culture (Fig. 2 C), 
suggesting that they died in culture. In summary, IL-7R+ cells 
have a high expansion potential, as is characteristic for memory 
cells, whereas IL-7R cells are anergic but proliferate in the 
presence of IL-2.
It was proposed that the lymph node homing receptors 
CCR7 or CD62L in combination with IL-7R expression 
defines subsets of central memory, effector memory, and ef-
fector cells (23, 24). Memory but not effector CD4+ T cells 
maintain their number by slow proliferation with homeostatic 
cytokines (19, 25). In addition, CCR7 effector memory 
T cells are more responsive to homeostatic cytokines than 
CCR7+ central memory T cells (26). We therefore compared 
the proliferative response of CD4+CD25 T cell subsets pu-
rified according to CCR7 and IL-7R expression to IL-7 
or IL-15 (Fig. 2 B). IL-7R+ subsets proliferated with IL-7 
and IL-15, showing a higher rate of proliferation in the 
CCR7 subset, as expected. In contrast, IL-7R cells that 
were also heterogeneous for CCR7 expression failed to prolif-
erate with IL-7, as expected. Notably, although CCR7IL-7R 
proliferated in response to IL-15, only few cells were recov-
ered from IL-15–driven cultures (Fig. 2 C), indicating that 
they failed to survive.
In summary, IL-7R cells have characteristics of effector 
cells because they produce high levels of effector cytokines and 
little IL-2, expand poorly upon TCR stimulation, and die in 
the presence of homeostatic cytokines.
CD4+CD25IL-7R cells were activated, effector-like cells 
that coproduced IL-10 and IFN- but not IL-2. These cells 
were largely Foxp3 but inhibited T cell proliferation in an 
IL-10–dependent manner, and might thus represent the human 
counterpart of mouse Tr1-like cells.
RESULTS AND DISCUSSION
Circulating CD4+IL-7R T cells coproduce IL-10 and IFN- 
but secrete little IL-2
We purified human antigen–experienced (CD45RA) CD4+ 
T cells according to CD25 and IL-7R expression, and ana-
lyzed Foxp3 expression to assess the presence of natural T reg 
cells in the resulting three populations (Fig. 1, A and B). The 
majority of the cells had a CD25/loIL-7Rhi memory pheno-
type (IL-7R+) and did not express Foxp3 (1 ± 1%). Consis-
tent with two previous reports (17, 18), the CD25+IL-7Rlo 
phenotype identified natural T reg cells (CD25+ T reg cells; 
5 ± 2%) that were mostly Foxp3+ (82 ± 16%). Finally, the 
smallest fraction of cells (IL-7R; 1 ± 1%) expressed neither 
CD25 nor IL-7R, and only a small fraction of these cells ex-
pressed Foxp3 (11 ± 6%).
We  analyzed  the  cytokine  profile  of  purified 
CD4+CD45RA T cell subsets after polyclonal activation 
with phorbole ester and calcium ionophore or immobilized 
anti-CD3 and anti-CD28 antibodies. As shown in Fig. 1 C, 
IL-7R  cells  expressed  high  levels  of  IL-10  under  both 
conditions but only low levels of IL-2, in particular upon 
more  physiological  stimulation  with  anti-CD3  and  anti-
CD28 antibodies. Conversely, the majority of IL-7R+ cells 
produced IL-2, but only very few cells produced IL-10 un-
der both conditions. In a group of 13 donors, a significantly 
higher portion of IL-10 producers was found in the IL-7R 
(9 ± 7%) compared with the IL-7R+ (1 ± 1%) compartment 
when stimulated with phorbol ester and calcium ionophore   
(Fig. 1 E). IL-7R+ cells also secreted higher levels of TNF- 
than  IL-7R  cells  (unpublished  data).  We  then  assessed 
if IL-7R T cells that secreted IL-10 coexpressed cyto-
kines that are characteristic for different Th cell lineages 
(Fig. 1 D). The cytokine expression after polyclonal re-
stimulation was compared between total CD4+CD45RA 
T cells and subsets purified according to CD25 and IL-7R   
expression. Total antigen-experienced CD4+ T cells ex-
pressed low levels of IL-10 and a substantial fraction of these 
cells coproduced IFN-, whereas only very few IL-10+ 
cells also secreted IL-4 or IL-17. The IL-10+ cells that co-
produced IFN- or IL-4 were strongly diminished among 
IL-7R+ cells and highly enriched among IL-7R cells. No-
tably, nearly all IL-7R cells that produced IL-10 also se-
creted IFN- (Fig. 1, D and E). Surprisingly, there were 
also some IL-10+ cells in the T reg cell fraction that co-
produced IFN- or IL-4, and CD25+ T reg cells con-
tained the highest fraction of cells that coproduced IL-17 
and IL-10. Although the IFN-–producing CD25+ T cells 
are most likely contaminating Foxp3 effector cells (Fig. 1 B), 
the  IL-17–producing  cells  could  also  represent  Foxp3/
RORt-coexpressing cells that were previously described JEM VOL. 206, May 11, 2009  1011
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amounts of IL-2 to allow for TCR-driven proliferation of 
IL-7R cells (Fig. 2 A). Proliferative responses to the persis-
tent pathogens Candida albicans and human CMV (HCMV), 
as well as to the self-antigen MelanA, could be readily detected 
in both IL-7R+ and IL-7R subsets. IL-7R+ cells also re-
sponded to a variety of vaccination antigens, including tetanus 
toxoid (TT), influenza hemagglutinin, and purified protein 
CD4+IL-7R T cells respond to persistent antigens
The IL-7R is down-regulated upon TCR stimulation (24), 
and human CD8 T cells that have down-regulated IL-7R ex-
pression are specific for persistent but not for cleared viruses (27). 
We  therefore  investigated  the  proliferative  responses  of 
CD4+IL-7R+ and IL-7R T cell subsets to persistent and 
vaccination antigens (Fig. 3, A and B) in the presence of low 
Figure 1.  Tr1-like cytokine profile of CD25IL-7R T cells. (A) CD25 and IL-7R expression on antigen-experienced human blood CD4+CD45RA 
T cells ex vivo. (B) Foxp3 expression in CD4+ T cell subsets purified according to CD25 and IL-7R expression assessed once in at least 11 different donors. 
(C) Purified CD25IL-7R and IL-7R+ subsets were stimulated with anti-CD3 and anti-CD28 antibodies or with phorbol 12,13-dibutyrate (PdBu) plus ion-
omycin, and IL-10 and IL-2 secretion were measured (percentages are shown). One representative experiment out of seven with seven different donors is 
shown. (D) Total CD4+CD45RA cells were compared with subsets defined by CD25 and IL-7R expression for the secretion of IL-10 and IFN- (top), IL-4 
(middle), and IL-17 (bottom). Percentages are shown. One representative experiment out of three performed with four different donors is shown. (E) Per-
centages of total IFN-+ cells (left), total IL-10+ cells (middle), and IFN-–producing cells among IL-10+ cells (right) in IL-7R, IL-7R+, and CD25+ subsets 
in 13 different donors. Horizontal bars represent means. *, P < 0.05; and **, P < 0.005.1012 CHARACTERIZATION OF HUMAN BLOOD TR1-LIKE CELLS | Häringer et al.
The IL-7R subset is enriched for cells that have been 
recently activated in vivo
The results so far suggested that IL-7R cells had been re-
cently activated by persistent antigens. To assess the recent pro-
liferation history of CD4+ T cell subsets, we performed ex 
vivo Ki-67 staining because it identifies circulating T cells 
that have proliferated in the last few days (28). As shown in 
Fig. 4 A, very few IL-7R+ cells were Ki-67+ (1 ± 1%), 
whereas substantial fractions not only of CD25+ T reg cells, 
as expected (4, 5), but in particular of IL-7R cells expressed 
this proliferation marker (15 ± 8% and 21 ± 10%, respectively). 
The different proliferation histories of the IL-7R+ and IL-7R 
subsets were also reflected by their phenotypes, because the 
activation markers ICOS and HLA-DR (Fig. 4, B and C) 
were expressed on comparable fractions of CD25+ T reg cells 
and IL-7R cells but not on IL-7R+ cells. We also analyzed 
the ex vivo expression levels of the antiapoptotic molecule 
Bcl-2 (Fig. 4 D), which is down-regulated by antigenic stim-
ulation but induced by homeostatic cytokines. Bcl-2 expres-
sion levels were high in IL-7R+ cells, lower in CD25+ T reg 
cells, as reported previously (6), and lowest in IL-7R cells, 
and therefore correlated with cell recovery in TCR- or cyto-
kine-driven cultures (Fig. 2). Finally, IL-7R cells expressed 
higher levels of the T reg cell marker CTLA-4 than IL-7R+ 
derivate (PPD) in vaccinated donors. Conversely, IL-7R cells 
responded poorly or not at all to these antigens in the same 
donors. However, in two donors that had been recently vac-
cinated against influenza and in one with recent tuberculosis 
infection,  IL-7R  cells  did  proliferate  with  hemagglutinin 
and PPD, respectively (unpublished data), consistent with the 
view that down-regulation of IL-7R in vivo reflects recent 
antigenic activation. To assess if antigen-specific IL-7R cells 
coproduced IFN- and IL-10, proliferating cells were restim-
ulated with autologous monocyte-derived DCs in the absence 
or presence of the relevant antigens. As shown in Fig. 3 C, a 
substantial fraction of IL-7R cells that had proliferated with 
HCMV or C. albicans coproduced IFN- and IL-10 upon 
antigen-specific restimulation. Conversely, IL-7R+ cells from 
the same donor produced only IFN- under the same condi-
tions. Cells specific for C. albicans but not for HCMV also 
produced IL-17 upon restimulation (unpublished data). More-
over, in three donors we were able to detect low levels of IL-10 
in IL-7R but not in IL-7R+ subsets in response to HCMV 
antigens after 24 h ex vivo by ELISA, whereas IFN- was de-
tected in the supernatants of both subsets (unpublished data). 
Collectively our results indicate that IL-7R cells can pro-
duce IFN- and IL-10 in response to persistent antigens un-
der steady-state conditions.
Figure 2.  Low expansion potential of IL-7R T cells in response to TCR stimulation and homeostatic cytokines. (A) Proliferative response of 
subsets purified according to CD25 and IL-7R expression in response to anti-CD3 antibodies in the absence or presence of exogenous IL-2 or co-stimu-
latory anti-CD28 antibodies. CFSE dilution of viable cells was assessed on day 4. One representative donor out of three is shown. (B) Proliferative response 
of subsets purified according to CCR7 and IL-7R expression in response to 25 ng/ml IL-7 or IL-15 on day 7. One representative donor out of four is 
shown. (C) The recovered number of cells after stimulation with IL-7, IL-15, or anti-CD3/28. Horizontal bars represent means. *, P < 0.05.JEM VOL. 206, May 11, 2009  1013
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antigens in vivo. Because IL-7R cells express low levels of 
Bcl-2 (Fig. 4 D), responded poorly to homeostatic cytokines 
in vitro (Fig. 2 B), are specific for persistent antigens (Fig. 3), 
and have a high turnover rate in vivo (Fig. 4 A), it is tempting 
cells after in vitro activation, and CD25+ T reg cells expressed 
the highest levels, as expected (Fig. 4 E). Collectively these 
results are consistent with the view that the IL-7R subset 
contains cells that have been recently activated by persistent 
Figure 3.  Antigen specificities of IL-7R T cells. (A) CFSE profiles of CD25IL-7R and IL-7R+ subsets in one donor after stimulation in the absence 
or presence of protein antigens derived from HCMV, MelanA, and TT on day 7. (B) Percentages of purified IL-7R and IL-7R+ cells that have diluted CFSE 
on day 7 in at least 20 different donors in response to HCMV (14 donors), C. albicans (Candida; 7 donors), MelanA (8 donors), influenza hemagglutinin 
(Flu; 6 donors), M. tuberculosis (PPD; 7 donors), and TT (6 donors). Significantly lower proliferation among IL-7R cells is indicated (*, P < 0.05; and  
**, P < 0.005). (C) IFN- versus IL-10 production of cells that had divided in response to HCMV or Candida in IL-7R+ and IL-7R subsets after restimulation 
with the relevant antigen. One representative experiment with different donors out of three (Candida) or five (HCMV) is shown.
Figure 4.  Activation marker expression in IL-7R T cell subsets. CD4+CD45RA T cell subsets identified by CD25 and IL-7R expression were ana-
lyzed once in at least seven healthy donors for the expression of (A) Ki-67, (B) ICOS, or (C) HLA-DR. Significant differences are indicated (**, P < 0.005). 
Horizontal bars represent means. (D and E) Intracellular expression of (D) Bcl-2 ex vivo and (E) CTLA-4 after stimulation of purified subsets. Histogram 
plots are representative of single experiments in at least three different donors.1014 CHARACTERIZATION OF HUMAN BLOOD TR1-LIKE CELLS | Häringer et al.
vation of IL-7R T cells required strong stimulation (Fig. 2 A 
and not depicted), whereas in vitro suppression of T cell 
priming is most efficient after weak stimulation of responder 
cells (29). In conventional in vitro suppression assays responder 
and suppressor T cell populations are stimulated by anti-CD3, 
PHA, or allogenic APCs that activate both populations simul-
taneously. We designed a novel in vitro suppression assay in 
which responder and suppressor T cell populations could be 
selectively stimulated with the superantigens toxic shock syn-
drome toxin (TSST) and staphylococcal enterotoxin B (SEB), 
respectively. For this aim, CFSE-labeled responder cells were 
to speculate that the persistence of these cells depends on 
chronic TCR stimulation. Consistent with this hypothesis, a 
subset of mouse CD4+ T cells was recently identified that rap-
idly turned over in response to TCR ligands in vivo, and that 
was distinct from memory-like cells that performed slow ho-
meostatic proliferation with IL-7 or IL-15 (25).
CD4+IL-7R T cells suppress upon strong TCR activation in 
an IL-10–dependent manner
The high IL-10–producing capacities of IL-7R T cells sug-
gested that they possessed suppressive potential. Optimal acti-
Figure 5.  Different requirements for suppression of CD25+ T reg cells and IL-7R cells. (A and B) CFSE-labeled SEB-hyporesponsive naive T cells 
were stimulated with DCs pulsed with TSST and different amounts of SEB in the presence of different TSST hyporesponsive T cell populations. Open histo-
grams show CFSE profiles of TCR-V2+ responder cells when naive control cells were present, whereas shaded histograms show the effects of the presence 
of IL-7R cells (top) or of CD25+ T reg cells (bottom). (A) CFSE profiles in the absence or presence of 50 pg/ml (low) or 1 ng/ml (high) SEB are representative 
of four independent experiments with different donors. (B) Suppression of naive cells (representative of 14 donors; left) or of IL-7R+ memory cells (repre-
sentative of 6 donors; right) in the absence or presence of IL-10 neutralization induced by CCR4IL-7R cells (top) or by CD25+ T reg cells (bottom).  
(C) Suppression induced by CCR4IL-7R cells (left) and by CD25+ T reg cells (right) in 14 different donors in the absence or presence of IL-10 neutralization. 
(D) Effects of T reg cell dilution on suppression in the absence or presence of anti–IL-10. The means of six independent experiments are shown.JEM VOL. 206, May 11, 2009  1015
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Human Tr1-like cells could so far be generated only in 
vitro, and this is to our knowledge the first report that iden-
tifies circulating human cells with a Tr1-like cytokine pro-
file and function in vivo. We show that these cells have a 
CD4+CD25IL-7R phenotype, are chronically activated by 
persistent antigens, and are effector-like cells that coproduce 
IL-10 and IFN- but not IL-2. They are distinct from natural 
CD25+ T reg cells and can inhibit naive and antigen-experi-
enced T cell activation in an IL-10–dependent manner. 
We therefore suggest that they might represent the human coun-
terpart of the mouse Tr1 cells or the IL-10–producing Th1 
cells that limit immunopathology in parasitic infections (15, 
16). The identification of circulating Tr1-like cells should fa-
cilitate their further characterization in human clinical studies.
MATERIALS AND METHODS
Media and reagents. Recombinant cytokines (IL-2, IL-4, IL-7, IL-15, and 
IL-10) were purchased from R&D Systems. For FACS sorting (FACSAria and 
FACSDiva; BD) and analysis (LSRII and FACSCalibur; BD), the following 
antibodies were used: CD4–Alexa Fluor 405 (TT1), CD19-Cy5 (BU12), 
CD45RA–Alexa Fluor 700/-Cy5/-FITC (4G11), and HLA-DR–Cy5 (L243; 
in-house conjugates); ICOS-PE, IL-7R–PE/–Bio, TCR-V2–FITC/-Bio, 
TCR-V3–, 12–, 14–, and 17–FITC, and CD25-FITC (Beckman Coulter); 
CD25-PE  (Miltenyi  Biotec);  CD25-  allophycocyanin  and  IL-17A–Alexa 
Fluor 647 (eBioscience); CD4–Alexa Fluor 700, CD14-Cy5, CCR4–Pe-
Cy7, IFN-–FITC, IL-10-PE/allophycocyanin, IL-2–allophycocyanin, and 
IL-4–PE  (BD);  streptavidin-allophycocyanin/–Pacific  blue  (Invitrogen); 
CCR7 (R&D Systems); and goat anti–mouse IgG2a–Bio (SouthernBiotech).
Cell  culture. PBMCs were obtained from buffy coats of healthy donors 
(DRK) by Ficoll-Hypaque gradient (Sigma-Aldrich). All experiments with pa-
tient material were approved by the local ethics committee (Charite Ethik-
kommision). DCs were labeled with CD1c-FITC and BDCA-4–PE antibodies 
and were positively selected with anti-FITC and anti-PE microbeads (Miltenyi 
Biotec), followed by sorting into pDC and mDC subsets by the exclusion of 
contaminating B cells (CD19+) and monocytes (CD14+). Monocytes were pu-
rified with anti-CD14 magnetic beads (Miltenyi Biotec). Naive and memory 
CD4+ T cell subsets were enriched with magnetic beads, and IL-7R/CD25–
expressing subsets were purified by cell sorting. Cells were cultured as de-
scribed previously (26). T cell stimulation was performed with 0.1 µM phorbol 
12,13-dibutyrate and 1 µg/ml ionomycin (Sigma-Aldrich), or with optimal 
concentrations of either immobilized anti-CD3 antibodies alone (2 µg/ml) or 
at 0.1 µg/ml in the presence of 6 µg/ml anti-CD28 antibodies (BD).
Intracellular stainings. Foxp3 staining was performed with the anti–hu-
man Foxp3 staining set (eBioscience) according to the manufacturer’s in-
structions.  Cytokine-producing  capacity  and  CTLA-4  expression  were 
assessed after stimulation for 6 and 4 h, respectively, and addition of 10 µg/ml   
Brefeldin A (Sigma-Aldrich) after 2 h. After fixation with 2% paraformal-
dehyde (PFA; Merck), cells were permeabilized with PBS/0.5% saponin 
(Sigma-Aldrich) and stained for cytokines. CTLA-4 was stained with anti–
CTLA-4 (BNI-3; BD) antibody followed by an FITC-coupled anti–mouse 
IgG2a antibody (SouthernBiotech). To examine Ki-67 and Bcl-2 expres-
sion, PBMCs were first labeled with antibodies against CD127, CD25, 
CD4, and CD45RA, fixed with 2% PFA, and stained with anti–Ki-67–
FITC  (BD)  in  PBS/0.5%  saponin  or  with  anti-Bcl2–FITC  (Dako)  in 
PBS/1% Tween (Sigma-Aldrich).
Analysis of antigen specificities. Antigen specificities were analyzed as 
previously described (26). 5 × 104 monocytes were incubated with antigens 
and CFSE-labeled autologous T cell subsets at a 1:1 ratio in medium with 
human serum. CFSE dilution was analyzed after 7 d of culture. The antigens 
used were HCMV lysate (1:1,000), 0.5 particles/ml of C. albicans extract 
rendered hyporesponsive to SEB by depleting TCR-V3–, 
12–, 14–, and 17–expressing cells, whereas unlabeled putative 
suppressor populations were depleted of TSST-responsive 
TCR-V2+ cells. T cell priming by TSST-loaded DCs was 
then analyzed by CFSE dilution of TCR-V2+ responder cells 
in the presence of TCR-V2 populations of CD25+ T reg 
cells, IL-7R cells, or naive control cells (Fig. 5 A) that were 
stimulated with different concentrations of SEB. IL-7R 
T cells suppressed poorly or not at all in the absence of SEB 
or at low SEB concentrations, but efficiently suppressed at 
high SEB concentrations, indicating that they required strong 
TCR stimulation for suppression. Conversely, CD25+ T reg 
cells strongly inhibited T cell priming even in the absence of 
SEB. Thus, CD25+ T reg cells either suppress efficiently upon 
weak stimulation of TCR-V2 cells by TSST, or alterna-
tively, strong stimulation of highly autoreactive CD25+ T reg 
cells by autologous DC could be sufficient for suppression. 
The suppression assay was done with a mixture of myeloid 
DCs (mDCs) and plasmacytoid DCs (pDCs), the two princi-
pal DC populations in human blood, because the former 
prime naive T cells more potently and the latter induce IL-10 
expression in T cells more efficiently. Nevertheless, IL-10–
dependent suppression by IL-7R cells was also observed 
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(provided by G. Gerna and D. Lilleri, Fondazione IRCCS Policlinico San 
Matteo, Pavia, Italy), 1 µg/ml rhMelanA, 1 µg/ml rh-hemagglutinin–influ-
enza A virus (both from Prospec-Tany TechnoGene), 2 µg/ml TT (Novar-
tis), and 1 µg/ml PPD of Mycobacterium tuberculosis (provided by M. Jacobsen, 
MPI Immunology, Berlin, Germany). 1 ng/ml IL-2 corresponding to 2.4 
IU/ml was added where indicated in the figures. In some experiments, anti-
gen specificity was confirmed by restimulation with autologous monocytes 
or monocyte-derived DCs and the relevant antigens (Fig. 3 C), including an 
overlapping peptide pool of MelanA (JPT Peptide Technologies; not   
depicted), followed by intracellular cytokine staining of CFSE T cells. 
In some experiments, cytokine production of antigen-specific cells was ana-
lyzed by ELISA, as described previously (26). In brief, irradiated monocytes 
preincubated with antigens were cultured 1:1 with autologous T cell subsets, 
and the release of cytokines was analyzed after 24 h of stimulation.
Suppression assay. Responder T cells were rendered hyporesponsive to 
SEB by depleting TCR-V3, 12, 14, and 17+ cells by cell sorting and labeled 
with CFSE. They were co-cultured at a 1:1 ratio with unlabeled regulatory 
subsets or naive control cells that were rendered hyporesponsive to TSST by 
depleting TCR-V2+ cells. 2–4 × 103 DCs (mDCs and pDCs at a 1:1 ratio) 
that had been pulsed with different concentrations of SEB and/or TSST 
(Sigma-Aldrich) for 30 min at 37°C were added as stimulators. After 5 d, cells 
were stained and TCR-V2+ cells analyzed for CFSE dilution by FACS. 
Where indicated in the figures, IL-10 was neutralized by the addition of 
anti–IL-10 and anti–IL-10R antibodies at 10 µg/ml (BD). To calculate the 
percent suppression, we set the CFSE mean fluorescence intensity (MFI) of 
undivided cells as 100% suppression and the MFI of TCR-V2+ cells in the 
presence of unlabeled naive TCR-V2 control cells as 0% suppression.
Statistics. Statistical significance was calculated using the two-tailed Student’s 
t test. P < 0.05 (*) and P < 0.005 (**) were regarded as statistically significant.
We thank C. Romagnani, A. Hauser, A. Scheffold, and A. Thiel for critical reading and 
comments. A special thanks to Dr. Knels from the Red Cross Blood Bank in Dresden, 
and to Prof. G. Gerna and Dr. D. Lilleri of the Virology Department of Pavia Hospital 
for providing us with the HCMV and C. albicans preparations. Furthermore, we 
would also like to thank the laboratory managers, and in particular T. Kaiser and  
K. Raba from the flow cytometry facility of the German Rheumatism Research 
Center for their invaluable support.
This work was supported by the Charité Medical School and the Deutsche 
Forschungsgemeinschaft (junior group grant SFB650 TPN01).
The authors have no conflicting financial interests.
Submitted: 7 October 2008
Accepted: 7 April 2009
REFERENCES
  1.  Sakaguchi, S. 2004. Naturally arising CD4+ regulatory t cells for immuno-
logic self-tolerance and negative control of immune responses. Annu. 
Rev. Immunol. 22:531–562. 
  2.  Shevach, E.M. 2001. Certified professionals: CD4+CD25+ suppressor 
T cells. J. Exp. Med. 193:F41–F46. 
  3.  Seddon, B., and D. Mason. 1999. Peripheral autoantigen induces regu-
latory T cells that prevent autoimmunity. J. Exp. Med. 189:877–882. 
  4.  Vukmanovic-Stejic,  M.,  Y.  Zhang,  J.E.  Cook,  J.M.  Fletcher,  A. 
McQuaid, J.E. Masters, M.H. Rustin, L.S. Taams, P.C. Beverley, D.C. 
Macallan, and A.N. Akbar. 2006. Human CD4+ CD25hi Foxp3+ reg-
ulatory T cells are derived by rapid turnover of memory populations in 
vivo. J. Clin. Invest. 116:2423–2433.
  5.  Fisson, S., G. Darrasse-Jeze, E. Litvinova, F. Septier, D. Klatzmann, R. 
Liblau, and B.L. Salomon. 2003. Continuous activation of autoreac-
tive CD4+ CD25+ regulatory T cells in the steady state. J. Exp. Med. 
198:737–746. 
  6.  Taams, L.S., J. Smith, M.H. Rustin, M. Salmon, L.W. Poulter, and A.N. 
Akbar. 2001. Human anergic/suppressive CD4(+)CD25(+) T cells: a 
highly differentiated and apoptosis-prone population. Eur. J. Immunol. 
31:1122–1131. JEM VOL. 206, May 11, 2009  1017
BRIEF DEFINITIVE REPORT
  25.  Purton, J.F., J.T. Tan, M.P. Rubinstein, D.M. Kim, J. Sprent, and C.D. 
Surh. 2007. Antiviral CD4+ memory T cells are IL-15 dependent. 
J. Exp. Med. 204:951–961. 
  26.  Rivino, L., M. Messi, D. Jarrossay, A. Lanzavecchia, F. Sallusto, and J. 
Geginat. 2004. Chemokine receptor expression identifies pre–T helper 
(Th)1, pre–Th2, and nonpolarized cells among human CD4+ central 
memory T cells. J. Exp. Med. 200:725–735. 
  27.  van Leeuwen, E.M., G.J. de Bree, E.B. Remmerswaal, S.L. Yong, K. 
Tesselaar, I.J. ten Berge, and R.A. van Lier. 2005. IL-7 receptor alpha 
chain expression distinguishes functional subsets of virus-specific human 
CD8+ T cells. Blood. 106:2091–2098. 
  28.  Pitcher, C.J., S.I. Hagen, J.M. Walker, R. Lum, B.L. Mitchell, V.C. 
Maino, M.K. Axthelm, and L.J. Picker. 2002. Development and ho-
meostasis of T cell memory in rhesus macaque. J. Immunol. 168:29–43.
  29.  George, T.C., J. Bilsborough, J.L. Viney, and A.M. Norment. 2003. 
High antigen dose and activated dendritic cells enable Th cells to es-
cape regulatory T cell-mediated suppression in vitro. Eur. J. Immunol. 
33:502–511. 
  30.  Iellem, A., M. Mariani, R. Lang, H. Recalde, P. Panina-Bordignon, 
F. Sinigaglia, and D. D’Ambrosio. 2001. Unique chemotactic response 
profile  and  specific  expression  of  chemokine  receptors  CCR4  and 
CCR8 by CD4+CD25+ regulatory T cells. J. Exp. Med. 194:847–853. 